-
Je něco špatně v tomto záznamu ?
Indication for a Single Postoperative Instillation of Chemotherapy in Non-muscle-invasive Bladder Cancer: What Factors Should Be Considered?
M. Babjuk, M. Burger, EM. Compérat, P. Gontero, HA. Mostafid, J. Palou, BWG. van Rhijn, M. Rouprêt, SF. Shariat, R. Sylvester, R. Zigeuner, O. Capoun, D. Cohen, JL. Dominguez-Escrig, V. Hernández, B. Peyronnet, T. Seisen, V. Soukup, European...
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články, směrnice pro lékařskou praxi
- MeSH
- antitumorózní látky aplikace a dávkování MeSH
- aplikace intravezikální MeSH
- cystektomie škodlivé účinky metody MeSH
- cystoskopie metody MeSH
- invazivní růst nádoru MeSH
- lidé MeSH
- lokální recidiva nádoru prevence a kontrola MeSH
- nádory močového měchýře * farmakoterapie patologie chirurgie MeSH
- pooperační péče metody MeSH
- zohlednění rizika MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- směrnice pro lékařskou praxi MeSH
An early single instillation of intravesical chemotherapy (SICI) used immediately after transurethral resection of the bladder (TURB) can significantly reduce the recurrence rate in selected patients with non-muscle-invasive bladder cancer (NMIBC). SICI should be used in patients with low-risk and with selected intermediate-risk tumours, in particular for multiple primary small papillary tumours, single primary papillary tumours >3cm, and single recurrent papillary tumours recurring >1yr after the previous resection. The available data do not support any recommendation to reduce the role of SICI in patients after fluorescence cystoscopy-guided TURB or en bloc TURB. SICI can even provide some benefit in patients with intermediate-risk tumours subsequently treated with further instillations. During instillation, contraindications should be taken into account and safety measures should be applied. PATIENT SUMMARY: An early single instillation of intravesical chemotherapy immediately after transurethral resection of the bladder can significantly reduce the recurrence rate in selected patients with non-muscle-invasive bladder cancer. It should be used in patients with low-risk and selected intermediate-risk tumours.
Department of Pathology Hôpital Tenon AP HP Sorbonne University Paris France
Department of Surgery and Cancer Imperial College London London UK
Department of Urology Caritas St Josef Medical Centre University of Regensburg Regensburg Germany
Department of Urology Fundació Puigvert Universidad Autónoma de Barcelona Barcelona Spain
Department of Urology Hôpital La Pitié Salpétrière AP HP Sorbonne University Paris France
Department of Urology Hospital Motol 2nd Faculty of Medicine Charles University Praha Czech Republic
Department of Urology Hospital Universitario Fundación Alcorcón Madrid Spain
Department of Urology Lister Hospital East and North Hertfordshire NHS Trust Stevenage UK
Department of Urology Medical University of Graz Graz Austria
Department of Urology Royal Surrey County Hospital Guildford UK
Department of Urology University of Texas Southwestern Medical Center Dallas TX USA
Department of Urology Weill Cornell Medical College New York NY USA
European Association of Urology Guidelines Office Brussels Belgium
Medical University of Vienna Vienna General Hospital Vienna Austria
Service d'Urologie CHU de Rennes Rennes France
Servicio de Urología Fundación Instituto Valenciano de Oncología Valencia Spain
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19028293
- 003
- CZ-PrNML
- 005
- 20190823120913.0
- 007
- ta
- 008
- 190813s2018 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.euf.2018.07.023 $2 doi
- 035 __
- $a (PubMed)30061076
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Babjuk, Marko $u Department of Urology, Hospital Motol, Second Faculty of Medicine, Charles University, Praha, Czech Republic; Medical University of Vienna, Vienna General Hospital, Vienna, Austria. Electronic address: marek.babjuk@fnmotol.cz.
- 245 10
- $a Indication for a Single Postoperative Instillation of Chemotherapy in Non-muscle-invasive Bladder Cancer: What Factors Should Be Considered? / $c M. Babjuk, M. Burger, EM. Compérat, P. Gontero, HA. Mostafid, J. Palou, BWG. van Rhijn, M. Rouprêt, SF. Shariat, R. Sylvester, R. Zigeuner, O. Capoun, D. Cohen, JL. Dominguez-Escrig, V. Hernández, B. Peyronnet, T. Seisen, V. Soukup, European Association of Urology Guidelines Panel on Non–muscle-invasive Bladder Cancer,
- 520 9_
- $a An early single instillation of intravesical chemotherapy (SICI) used immediately after transurethral resection of the bladder (TURB) can significantly reduce the recurrence rate in selected patients with non-muscle-invasive bladder cancer (NMIBC). SICI should be used in patients with low-risk and with selected intermediate-risk tumours, in particular for multiple primary small papillary tumours, single primary papillary tumours >3cm, and single recurrent papillary tumours recurring >1yr after the previous resection. The available data do not support any recommendation to reduce the role of SICI in patients after fluorescence cystoscopy-guided TURB or en bloc TURB. SICI can even provide some benefit in patients with intermediate-risk tumours subsequently treated with further instillations. During instillation, contraindications should be taken into account and safety measures should be applied. PATIENT SUMMARY: An early single instillation of intravesical chemotherapy immediately after transurethral resection of the bladder can significantly reduce the recurrence rate in selected patients with non-muscle-invasive bladder cancer. It should be used in patients with low-risk and selected intermediate-risk tumours.
- 650 _2
- $a aplikace intravezikální $7 D000283
- 650 _2
- $a antitumorózní látky $x aplikace a dávkování $7 D000970
- 650 _2
- $a cystektomie $x škodlivé účinky $x metody $7 D015653
- 650 _2
- $a cystoskopie $x metody $7 D003558
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a invazivní růst nádoru $7 D009361
- 650 _2
- $a lokální recidiva nádoru $x prevence a kontrola $7 D009364
- 650 _2
- $a pooperační péče $x metody $7 D011182
- 650 _2
- $a zohlednění rizika $7 D020379
- 650 12
- $a nádory močového měchýře $x farmakoterapie $x patologie $x chirurgie $7 D001749
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a směrnice pro lékařskou praxi $7 D017065
- 700 1_
- $a Burger, Maximilian $u Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany.
- 700 1_
- $a Compérat, Eva M $u Department of Pathology, Hôpital Tenon, AP-HP, Sorbonne University, Paris, France.
- 700 1_
- $a Gontero, Paolo $u Department of Urology, San Giovanni Battista Hospital, Città della Salute e della Scienza, University of Turin, Turin, Italy.
- 700 1_
- $a Mostafid, Hugh A $u Department of Urology, Royal Surrey County Hospital, Guildford, UK.
- 700 1_
- $a Palou, Joan $u Department of Urology, Fundació Puigvert, Universidad Autónoma de Barcelona, Barcelona, Spain.
- 700 1_
- $a van Rhijn, Bas W G $u Department of Urology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
- 700 1_
- $a Rouprêt, Morgan $u Department of Urology, Hôpital La Pitié-Salpétrière, AP-HP, Sorbonne University, Paris, France.
- 700 1_
- $a Shariat, Shahrokh F $u Department of Urology, Hospital Motol, Second Faculty of Medicine, Charles University, Praha, Czech Republic; Medical University of Vienna, Vienna General Hospital, Vienna, Austria; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Department of Urology, Weill Cornell Medical College, New York, NY, USA.
- 700 1_
- $a Sylvester, Richard $u European Association of Urology Guidelines Office, Brussels, Belgium.
- 700 1_
- $a Zigeuner, Richard $u Department of Urology, Medical University of Graz, Graz, Austria.
- 700 1_
- $a Capoun, Otakar $u Department of Urology, General University Hospital, First Faculty of Medicine, Charles University, Prague, Czech Republic.
- 700 1_
- $a Cohen, Daniel $u Department of Surgery and Cancer, Imperial College London, London, UK; Department of Urology, Lister Hospital, East and North Hertfordshire NHS Trust, Stevenage, UK.
- 700 1_
- $a Dominguez-Escrig, José L $u Servicio de Urología, Fundación Instituto Valenciano de Oncología, Valencia, Spain.
- 700 1_
- $a Hernández, Virginia $u Department of Urology, Hospital Universitario Fundación Alcorcón, Madrid, Spain.
- 700 1_
- $a Peyronnet, Benoit $u Service d'Urologie, CHU de Rennes, Rennes, France.
- 700 1_
- $a Seisen, Thomas $u Department of Urology, Hôpital La Pitié-Salpétrière, AP-HP, Sorbonne University, Paris, France.
- 700 1_
- $a Soukup, Viktor $u Department of Urology, General University Hospital, First Faculty of Medicine, Charles University, Prague, Czech Republic.
- 710 2_
- $a European Association of Urology Guidelines Panel on Non–muscle-invasive Bladder Cancer
- 773 0_
- $w MED00193513 $t European urology focus $x 2405-4569 $g Roč. 4, č. 4 (2018), s. 525-528
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30061076 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190813 $b ABA008
- 991 __
- $a 20190823121127 $b ABA008
- 999 __
- $a ok $b bmc $g 1433442 $s 1066753
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 4 $c 4 $d 525-528 $e 20180727 $i 2405-4569 $m European urology focus $n Eur Urol Focus $x MED00193513
- LZP __
- $a Pubmed-20190813
